TEST:

CanAssist Breast

"Ahmedabad-based Zydus Lifesciences has announced that it will be exclusively marketing CanAssist Breast, an innovative and a highly advanced prognostic test for breast cancer patients in the early stages to help clinicians decide whether the patient needs chemotherapy or not."

"Accurate risk stratification of European patients by CAB coupled with its similar performance inIndian patients shows that CAB is robust and functions independent of ethnic differences. CAB can potentially prevent overtreatment in a greater number of patients compared to IHC4 demonstrating its usefulness for adjuvant systemic therapy planning in European breast cancer patients."